Scanvio

What Scanvio does

Scanvio Medical AG is an ETH Zurich spin-off incorporated in May 2024 that develops AI-assisted ultrasound software (Scanvio Assist™ / Scanvio AI Assistant™) for the early diagnosis of endometriosis. The software applies proprietary deep learning models to analyze transvaginal ultrasound video in real time, providing live feedback to gynecologists during examinations, highlighting relevant pelvic structures, detecting nodules and adhesions, mapping disease spread, and generating standardized diagnostic reports. The company targets three customer segments in parallel: individual gynecologists seeking reliable endometriosis diagnosis during routine ultrasound; specialized endometriosis centers requiring standardized, trackable diagnostic workflows; and ultrasound manufacturers (OEMs) seeking AI differentiation to embed as a software add-on in their existing platforms.

The underlying technology was developed at ETH Zurich's Institute for Machine Learning and AI Center, with team members holding PhDs in deep learning for medical imaging and publications at NeurIPS, CVPR, MICCAI, and ECCV. The clinical product is validated through partnerships with University Hospital Zurich's Endometriosis Unit (co-founder-led by Dr. Julian Metzler), Prof. Jörg Keckstein's Certified Endometriosis Centre in Villach, Austria, and Ifakara Health Institute in Tanzania.

Commercially, the company pursues a multi-channel go-to-market: direct enterprise sales to endometriosis centers and hospital systems (demo-driven, Calendly-mediated), OEM integration partnerships for embedded distribution through incumbent ultrasound platforms, and event-driven awareness building at medical imaging conferences. Revenue mechanics are subscription/recurring software licensing plus OEM integration fees, though pricing has not been publicly disclosed. The product is currently undergoing CE conformity assessment under EU MDR 2017/745 and is not yet available for sale, distribution, or clinical use in the EU or other jurisdictions; US regulatory clearance is planned. The company has raised approximately USD 3.4M in seed funding (July 2025), CHF 200K in Venture Kick grants across three stages, and additional non-dilutive funding from Innosuisse, EPFL's Future of Health Grant, InnoBooster, and the NVIDIA Inception Program.

Name

Scanvio

Legal name

Scanvio Medical AG

Website

https://scanvio.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Scanvio Medical is an ETH Zurich spin-off that develops AI-assisted ultrasound software (Scanvio Assist) for real-time endometriosis diagnosis during transvaginal examinations, serving gynecologists, endometriosis centers, and ultrasound manufacturers; the product is currently pre-commercial pending CE marking under EU MDR.

Ownership category

akta.pro rank

Product category

AI-Assisted Medical Imaging Software

NAICS

Computer Systems Design and Related Services (54151)

SIC

Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ)

akta.pro secondary industries

Diagnostic & Triage Decision Support (HLACAGAA), SaMD – Monitoring, Triage & Risk Stratification Software (HLACANAE), Radiology Reporting, Dictation & Structured Reporting (HLACALAF)

Keywords

• AI ultrasound software
• Endometriosis diagnosis
• Medical imaging AI
• Transvaginal ultrasound analysis
• Women's health diagnostics

Headquarters

HQ city

Zürich

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Software License/Subscription: Scanvio Assist sold as software add-on to ultrasound manufacturers and healthcare systems. Likely subscription or licensing model for ongoing software updates and support.
2. OEM Integration: Integration fees from ultrasound manufacturers who embed Scanvio AI Assistance into their existing platforms as a software add-on.
3. Clinical Service Partnerships: Partnerships with endometriosis centers and healthcare systems for deployment of AI-assisted ultrasound diagnostic solutions.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

Scanvio develops AI-assisted ultrasound software (Scanvio Assist™) that analyzes ultrasound video in real time during transvaginal examinations to detect signs of endometriosis, highlight relevant pelvic structures, and produce standardized diagnostic reports. The software is designed to be integrated either directly into clinical workflows at endometriosis centers or embedded as a software add-on within ultrasound manufacturers' platforms, enabling non-expert gynecologists to reliably diagnose endometriosis.

Product overview

Scanvio offers a unified AI-assisted ultrasound software platform (Scanvio Assist / Scanvio AI Assistant) designed to democratize expert-level endometriosis diagnosis. The core product is a single software solution that integrates into existing ultrasound platforms as an add-on, targeting three distinct market segments: individual clinicians (routine transvaginal examinations with standardized reporting), endometriosis centers (efficient diagnostic workflows with structured visualization), and ultrasound manufacturers (OEM integration). The product uses real-time AI analysis of ultrasound video to provide live guidance during examinations, reducing diagnostic delays from 4-12 years to 1-3 years.

Differentiator

Problem solved

Functional benefit

Brands

• Scanvio Assist™: AI-assisted ultrasound software for endometriosis diagnosis that provides real-time AI-assisted image assessment to support gynecologists during ultrasound examinations.
• Scanvio AI Assistant™

Products and services

• Scanvio Assist (also marketed as Scanvio AI Assistant)

Quantifiable outcome

• Reduces diagnostic delay from 4-12 years to 1-3 years by placing AI-assisted diagnosis at beginning of clinical pathway
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Six partnerships are on record, tiered supporting, core and minor.

• NVIDIA Inception ProgramsupportingTechnology or Integration · 10 May 2024Scanvio joined the NVIDIA Inception program, an elite group of startups driving change across industries. The program provides startups with access to NVIDIA's technical resources, hardware, and expertise for AI development.
• ETH ZurichcoreStrategic or Co-development Partner · 1 January 2024ETH Zurich is the parent institution and spin-off origin of Scanvio Medical. The company emerged from the ETH AI Center and Institute for Machine Learning. Team members completed PhDs at ETH Zurich. Strategic research support provided within surgery, medtech and health-related activities.
• University Hospital ZurichcoreStrategic or Co-development Partner · 1 January 2024Clinical validation partner with Julian Metzler (Head Endometriosis Unit) as co-founder and medical advisor. The Endometriosis Center at University Hospital Zurich provides clinical expertise, validation, and testing for the Scanvio AI-assisted ultrasound solution.
• Ifakara Health InstituteminorStrategic or Co-development PartnerInternational clinical partnership in Tanzania for bringing state-of-the-art endometriosis care to East Africa. Represents potential market expansion and global health impact collaboration.
• Prof. Dr. med. Jörg KecksteincoreStrategic or Co-development PartnerClinical advisory partnership with Prof. Keckstein, Adjunct Professor at University Ulm, Past Chair of ESGE SIG Endometriosis, WES Ambassador, and lead of Dres. Keckstein Certified Endometriosis Centre in Villach, Austria. Provides expert validation and credibility in endometriosis field.
• University of BernsupportingStrategic or Co-development PartnerResearch collaboration with University of Bern, including Senior AI/ML Engineer Dr. Sergio Tascon-Morales who completed PhD research in Visual Question Answering at University of Bern with publications at CVPR and MICCAI.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Butterfly Network: Pocket-sized ultrasound platform with integrated AI (Auto-IMT, bladder volume, etc.) used across multiple clinical settings. Comparable in pursuing AI-on-ultrasound as a democratization play, though focused on portable hardware rather than specialty disease AI.
• Mindray: Major global ultrasound OEM with growing embedded AI capabilities (e.g., smart-plane, smart-fetal). A potential OEM partner for Scanvio and also a structural threat if it develops in-house endometriosis AI features on its own installed base.
• Philips Ultrasound: Top-three global ultrasound OEM with AI-enabled platforms (e.g., EPIQ, Affiniti). Strategic OEM candidate and competitor, given its active roadmap in AI-augmented imaging workflows across clinical specialties.
• GE HealthCare: Largest ultrasound OEM globally and acquirer of Caption Health, with broad AI investments across imaging. Most important potential OEM distribution partner for Scanvio and the largest competitive risk if it builds or buys endometriosis imaging AI.

Direct peers

• Koios Medical: AI clinical decision support software that interprets ultrasound images (initially breast and thyroid) and integrates with OEM ultrasound platforms. Highly comparable model of CAD-style AI guidance on ultrasound video for clinicians.
• Caption Health: AI software that guides clinicians through ultrasound image acquisition and interpretation (originally cardiac, now broader). Most direct comparable in AI-assisted ultrasound guidance; was acquired by GE HealthCare in 2023, illustrating both the strategic value of the category and the OEM-acquisition risk Scanvio faces.
• UltraSight: AI-guided cardiac ultrasound for point-of-care use, with FDA clearance. Comparable in applying deep learning to real-time ultrasound video to enable non-expert operators, sharing Scanvio's democratization thesis but in a different clinical specialty.
• Intelligent Ultrasound: AI-based ultrasound simulation, training, and real-time image analysis tools (e.g., ScanNav, AIAS) sold to clinicians and integrated with ultrasound OEMs. Closely comparable business model of selling AI workflow/guidance software into ultrasound clinical practice and OEM channels.

Emerging players

• Exo Imaging: Developer of a portable ultrasound platform with embedded AI for workflow and image interpretation. Overlaps with Scanvio on real-time AI-driven ultrasound guidance, but Exo is a hardware-plus-software play focused on point-of-care use rather than a women's-health indication.
• DotLab: Diagnostics company developing a blood-based biomarker test for endometriosis. Addresses the same disease and patient population as Scanvio but with a different (non-imaging) diagnostic modality, positioning it as a complementary or competing diagnostic pathway.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/scanvio-medical

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds5 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scanvio